
Validea's guru fundamental report indicates that Johnson & Johnson (JNJ) receives a strong 87% rating based on their Multi-Factor Investor model, which is based on the strategy of Pim van Vliet. The model favors low volatility stocks with strong momentum and high net payout yields, with JNJ passing the market cap and standard deviation tests, while receiving a neutral rating for momentum and net payout yield. Van Vliet's research suggests that low volatility stocks can outperform high volatility stocks with less risk.
Johnson & Johnson (JNJ) has received a favorable rating of 87% from Validea's Multi-Factor Investor model, resulting in a "PASS" for its final rank under this strategy developed by Pim van Vliet, which prioritizes low volatility stocks exhibiting strong momentum and high net payout yields. This score signifies a notable interest in JNJ, approaching the model's threshold for strong interest (above 90%). As a large-cap growth stock in the Biotechnology & Drugs industry, JNJ successfully meets the model's criteria for market capitalization and standard deviation, underscoring its alignment with the low-volatility factor. However, JNJ received neutral ratings for "Twelve Minus One Momentum" and "Net Payout Yield," indicating these aspects are not currently primary strengths according to this specific multi-factor assessment. The overall positive ticker-specific sentiment (0.7) for JNJ is consistent with the model's generally positive evaluation, which is based on the premise that conservatively profiled, low-risk stocks can offer superior risk-adjusted returns.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment